

Ileana Soto Mauldin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6854415/publications.pdf>

Version: 2024-02-01

22
papers

651
citations

759233

12
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

1120
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures. <i>Methods in Molecular Biology</i> , 2021, 2265, 573-587.	0.9	7
2	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. , 2021, 9, e002273.		39
3	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. <i>Cell Reports</i> , 2021, 36, 109422.	6.4	89
4	Immunotyping and Quantification of Melanoma Tumorâ€“Infiltrating Lymphocytes. <i>Methods in Molecular Biology</i> , 2021, 2265, 515-528.	0.9	2
5	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>Oncolmmunology</i> , 2021, 10, 1898105.	4.6	11
6	Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma. <i>Cells</i> , 2021, 10, 3378.	4.1	24
7	Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry. <i>Methods in Enzymology</i> , 2020, 635, 81-93.	1.0	3
8	Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1121-1132.	4.2	13
9	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. <i>Journal of Immunology</i> , 2018, 200, 432-442.	0.8	153
10	Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. <i>Melanoma Research</i> , 2018, 28, 237-245.	1.2	35
11	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1490855.	4.6	10
12	Perivascular Adipose Tissue Harbors Atheroprotective IgM-Producing B Cells. <i>Frontiers in Physiology</i> , 2017, 8, 719.	2.8	43
13	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. <i>Oncolmmunology</i> , 2016, 5, e1240857.	4.6	56
14	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1189-1199.	4.2	38
15	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1201-1212.	4.2	36
16	A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 25-36.	4.2	30
17	Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multi-peptide melanoma vaccine. , 2015, 3, .		1
18	Cytokines and TLR agonists influence the expression of retention integrins CD49a, CD49b and CD103 by T cells. , 2015, 3, .		0

#	ARTICLE	IF	CITATIONS
19	Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival. <i>Clinical Cancer Research</i> , 2015, 21, 3879-3887.	7.0	33
20	TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. <i>International Journal of Cancer</i> , 2015, 137, 1386-1396.	5.1	25
21	TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling. , 2014, 2, .		3
22	TLR2/6 agonists and IFN γ synergize to induce melanoma cells to produce T-cell recruiting chemokines. , 2013, 1, .		0